Oakmont Investment Advisors’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.27M Buy
1,058
+803
+315% +$820K 0.88% 32
2026
Q1
$235K Buy
255
+10
+4% +$10.1K 0.21% 93
2025
Q4
$264K Buy
+245
New +$234K 0.19% 99

Other funds holding LLY

Oakmont Investment Advisors's LLY Position: Q2 2026 in Review

Oakmont Investment Advisors increased its Eli Lilly (LLY) stake by 315% in Q2 2026, buying an estimated $820K and bringing the position to 1,058 shares worth $1.27M. The position accounts for 0.88% of the portfolio, ranked #32.

Oakmont Investment Advisors first reported a position in LLY in Q4 2025 and has held it in 3 quarters since. 4,593 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • Oakmont Investment Advisors held 1,058 shares of Eli Lilly worth $1.27M as of Q2 2026.
  • Oakmont Investment Advisors bought 803 Eli Lilly shares in Q2 2026, an estimated $820K.
  • Eli Lilly made up 0.88% of Oakmont Investment Advisors's portfolio in Q2 2026, its #32 holding.
  • Oakmont Investment Advisors first reported a position in Eli Lilly in Q4 2025 and has held it in 3 quarters since.
  • 4,593 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on Oakmont Investment Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.